









Markets
/
Stocks
/
nasdaq-scyx
/

SCYNEXIS Inc

SCYX

0.759USD

+0.069+9.94%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

31.85MMarket Cap

LossP/E TTM



SCYNEXIS Inc

0.759

+0.069+9.94%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of SCYNEXIS Inc

Currency: USD Updated: 2026-02-06

Key Insights

SCYNEXIS Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 98 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 3.67.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

SCYNEXIS Inc's Score

Industry at a Glance

Industry Ranking

98 / 159

Overall Ranking

263 / 4521

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

SCYNEXIS Inc Highlights

StrengthsRisks

SCYNEXIS, Inc. is a biotechnology company. It is pioneering medicine to overcome and prevent difficult-to-treat and drug-resistant infections. It is developing its antifungal platform fungerps, a class of antifungal agents called triterpenoids, that are structurally distinct glucan synthase inhibitors and have shown in vitro and in vivo activity against a range of human fungal pathogens such as Candida and Aspergillus genera, including multidrug-resistant strains, as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and common mucorales species. Ibrexafungerp is the first representative of this class of antifungals with additional assets from the fungerp family under development, including SCY-247, which is in clinical stages of development. The United States Food and Drug Administration approved BREXAFEMME (ibrexafungerp tablets) for treatment of patients with vulvovaginal candidiasis, and for the reduction in the incidence of recurrent vulvovaginal candidiasis.

Growing

The company is in a growing phase, with the latest annual income totaling USD 3.75M.

Turnaround to Loss

The company's performance has turned to a loss, with the latest annual loss of USD .

Fairly Valued

The company’s latest PE is -1.49, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 13.62M shares, increasing 9.48% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 174.60K shares of this stock.

Analyst Rating

Based on 3 analysts

Buy

Current Rating

3.667

Target Price

+431.09%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of SCYNEXIS Inc is 6.12, ranking 148 out of 159 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 334.00K, representing a year-over-year decrease of 49.39%, while its net profit experienced a year-over-year decrease of 205.95%.

Score

Industry at a Glance

Previous score

6.12

Change



Financials

7.37

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.68

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.83

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

5.64

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.07

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

SCYNEXIS Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of SCYNEXIS Inc is 7.64, ranking 54 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is -1.49, which is -380.55% below the recent high of 4.17 and -122.41% above the recent low of -3.30.

Score

Industry at a Glance

Previous score

7.64

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 98/159

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of SCYNEXIS Inc is 8.67, ranking 13 out of 159 in the Pharmaceuticals industry. The average price target is 4.00, with a high of 4.00 and a low of 3.00.

Score

Industry at a Glance

Previous score

8.67

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 3 analysts

Buy

Current Rating

3.667

Target Price

+431.09%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

173

Total

Median

Average

Company name

Ratings

Analysts

SCYNEXIS Inc

SCYX

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Eli Lilly and Co

LLY

Gilead Sciences Inc

GILD

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of SCYNEXIS Inc is 6.29, ranking 130 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 0.87 and the support level at 0.64, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.89

Change

0.4

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(5)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.005

Neutral

RSI(14)

57.391

Neutral

STOCH(KDJ)(9,3,3)

36.548

Neutral

ATR(14)

0.069

High Vlolatility

CCI(14)

6.477

Neutral

Williams %R

47.537

Neutral

TRIX(12,20)

0.675

Sell

StochRSI(14)

82.397

Buy

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

0.734

Buy

MA10

0.749

Buy

MA20

0.716

Buy

MA50

0.671

Buy

MA100

0.726

Buy

MA200

0.781

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of SCYNEXIS Inc is 3.00, ranking 93 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 32.47%, representing a quarter-over-quarter increase of 35.53%. The largest institutional shareholder is The Vanguard, holding a total of 1.76M shares, representing 4.20% of shares outstanding, with 1.09% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Federated Hermes Global Investment Management Corp.

1.58M

-45.31%

Avidity Partners Management LP

3.35M

+172.64%

Kingdon Capital Management, L.L.C.

2.24M

The Vanguard Group, Inc.

Star Investors

1.76M

+6.37%

Angulo (Gonzalez David)

355.78K

+10.05%

Geode Capital Management, L.L.C.

419.45K

+0.23%

Acadian Asset Management LLC

416.60K

-1.86%

BlackRock Institutional Trust Company, N.A.

334.65K

Sukenick (Scott)

185.75K

+7.76%

AMH Equity, Ltd.

245.94K

-5.80%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of SCYNEXIS Inc is 3.19, ranking 107 out of 159 in the Pharmaceuticals industry. The company's beta value is 1.34. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.